.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,686,567

« Back to Dashboard

Details for Patent: 5,686,567

Title: Platelet aggregation inhibitors
Abstract:An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolated and purified PAI from several of these active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K*-(G/Sar)-D wherein K is a modified lysyl residue of the formula wherein each R.sup.1 is independently H, alkyl(1-6C) or at most one R.sup.1 is R.sup.2 --C.dbd.NR.sup.3 wherein R.sup.2 is H, alkyl(1-6C), phenyl or benzyl, or is NR.sup.4.sub.2 in which each R.sup.4 is independently H or alkyl(1-6C) and R.sup.3 is H, alkyl(1-6C), phenyl or benzyl, or R.sup.2 --C.dbd.NR.sup.3 is a radical selected from the group consisting of: ##STR1## where m is an integer of 2-3, and each R.sup.5 is independently H or alkyl(1-6C); and wherein one or two (CH.sub.2) may be replaced by O or S provided said O or S is not adjacent to another heteroatom are prepared and shown to specifically inhibit the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa.
Inventor(s): Scarborough; Robert M. (Belmont, CA), Wolf; David Lawrence (Palo Alto, CA), Charo; Israel F. (Lafayette, CA)
Assignee: COR Therapeutics, Inc. (San Francisco, CA)
Filing Date:Jun 05, 1995
Application Number:08/462,698
Claims:1. A compound of the formula: ##STR10## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, G or Sar is G, AA.sub.2 is O-methyltyrosine, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR11## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

2. A compound according to claim 1 having the formula:

3. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 2.

4. A compound comprising a platelet aggregation inhibitor of the formula: ##STR12## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, G or Sar is G, AA.sub.2 is O-methyltyrosine, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR13## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

5. A compound according to claim 4, the platelet aggregation inhibitor having the formula: ##STR14##

6. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 5.

7. A compound consisting essentially of a platelet aggregation inhibitor that inhibits (a) binding of Fg or vWF to GP IIb-IIIa more than (b) binding of vitronectin to vitronectin receptor or fibronectin to fibronectin receptor, which platelet aggregation inhibitor has the formula: ##STR15## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, G or Sar is G, AA.sub.2 is O-methyltyrosine, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR16## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

8. A compound according to claim 7, having the formula: ##STR17##

9. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 8.

10. A pharmaceutical composition which comprises a compound as in any one of claims 1-9 in admixture with a pharmaceutically acceptable excipient.

11. The compound of claim 10, wherein said compound is present in an amount effective to inhibit platelet aggregation.

12. A compound of the formula: ##STR18## wherein Y.sub.1 -X.sub.1 is Acetyl-Cys, n1 is 0, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR19## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

13. A compound according to claim 12 having the formula: ##STR20##

14. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 13.

15. A compound comprising a platelet aggregation inhibitor of the formula: ##STR21## wherein Y.sub.1 -X.sub.1 is Acetyl-Cys, n1 is 0, G or Sar is G, AA.sub. 2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR22## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

16. A compound according to claim 15, the platelet aggregation inhibitor having the formula: ##STR23##

17. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 16.

18. A compound consisting essentially of a platelet aggregation inhibitor that inhibits (a) binding of Fg or vWF to GP IIb-IIIa more than (b) binding of vitronectin to vitronectin receptor or fibronectin to fibronectin receptor, which platelet aggregation inhibitor has the formula: ##STR24## wherein Y.sub.1 -X.sub.1 is Acetyl-Cys, n1 is 0, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR25## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

19. A compound according to claim 18, having the formula: ##STR26##

20. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 19.

21. A pharmaceutical composition which comprises a compound according to any of claim 12-20 in admixture with a pharmaceutically acceptable excipient.

22. The compound of claim 21, wherein said compound is present in an amount effective to inhibit platelet aggregation.

23. A compound of the formula: ##STR27## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is penicillamine, Y.sub.2 is NH.sub.2, and ##STR28## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

24. A compound according to claim 23 having the formula: ##STR29##

25. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 24.

26. A compound comprising a platelet aggregation inhibitor of the formula: ##STR30## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is penicillamine, Y.sub.2 is NH.sub.2, and ##STR31## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

27. A compound according to claim 26, the platelet aggregation inhibitor having the formula: ##STR32##

28. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 27.

29. A compound consisting essentially of a platelet aggregation inhibitor that inhibits (a) binding of Fg or vWF to GP IIb-IIIa more than (b) binding of vitronectin to vitronectin receptor or fibronectin to fibronectin receptor, which platelet aggregation inhibitor has the formula: ##STR33## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is penicillamine, Y.sub.2 is NH.sub.2, and ##STR34## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

30. A compound according to claim 29, having the formula: ##STR35##

31. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 30.

32. A pharmaceutical composition which comprises a compound according to any of claim 23-31 in admixture with a pharmaceutically acceptable excipient.

33. The compound of claim 32, wherein said compound is present in an amount effective to inhibit platelet aggregation.

34. A compound of the formula: ##STR36## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is acetimidyl-Lys, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR37## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

35. A compound according to claim 34 having the formula: ##STR38##

36. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 35.

37. A compound comprising a platelet aggregation inhibitor of the formula: ##STR39## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is acetimidyl-Lys, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR40## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

38. A compound according to claim 37, the platelet aggregation inhibitor having the formula: ##STR41##

39. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 38.

40. A compound consisting essentially of a platelet aggregation inhibitor that inhibits (a) binding of Fg or vWF to GP IIb-IIIa more than (b) binding of vitronectin to vitronectin receptor or fibronectin to fibronectin receptor, which platelet aggregation inhibitor has the formula: ##STR42## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is acetimidyl-Lys, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR43## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

41. A compound according to claim 40, having the formula: ##STR44##

42. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 41.

43. A pharmaceutical composition which comprises a compound according to any of claim 34-42 in admixture with a pharmaceutically acceptable excipient.

44. The compound of claim 43, wherein said compound is present in an amount effective to inhibit platelet aggregation.

45. A compound of the formula: ##STR45## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is acetimidyl-Lys, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is penicillamine, Y.sub.2 is NH.sub.2, and ##STR46## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

46. A compound according to claim 45 having the formula: ##STR47##

47. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 46.

48. A compound comprising a platelet aggregation inhibitor of the formula: ##STR48## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is acetimidyl-Lys, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is penicillamine, Y.sub.2 is NH.sub.2, and ##STR49## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

49. A compound according to claim 48, the platelet aggregation inhibitor having the formula: ##STR50##

50. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 49.

51. A compound consisting essentially of a platelet aggregation inhibitor that inhibits (a) binding of Fg or vWF to GP IIb-IIIa more than (b) binding of vitronectin to vitronectin receptor or fibronectin to fibronectin receptor, which platelet aggregation inhibitor has the formula: ##STR51## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is acetimidyl-Lys, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is penicillamine, Y.sub.2 is NH.sub.2, and ##STR52## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

52. A compound according to claim 51, having the formula: ##STR53##

53. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 52.

54. A pharmaceutical composition which comprises a compound according to any of claim 45-53 in admixture with a pharmaceutically acceptable excipient.

55. The compound of claim 54, wherein said compound is present in an amount effective to inhibit platelet aggregation.

56. A compound of the formula: ##STR54## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is N.sup.G,N.sup.G '-ethylene-Har, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR55## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

57. A compound according to claim 56 having the formula: ##STR56##

58. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 57.

59. A compound comprising a platelet aggregation inhibitor of the formula: ##STR57## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is N.sup.G,N.sup.G '-ethylene-Har, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR58## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

60. A compound according to claim 59, the platelet aggregation inhibitor having the formula: ##STR59##

61. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 60.

62. A compound consisting essentially of a platelet aggregation inhibitor that inhibits (a) binding of Fg or vWF to GP IIb-IIIa more than (b) binding of vitronectin to vitronectin receptor or fibronectin to fibronectin receptor, which platelet aggregation inhibitor has the formula: ##STR60## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is N.sup.G,N.sup.G '-ethylene-Har, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR61## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

63. A compound according to claim 62, having the formula: ##STR62##

64. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 63.

65. A pharmaceutical composition which comprises a compound according to any of claim 56-64 in admixture with a pharmaceutically acceptable excipient.

66. The compound of claim 65, wherein said compound is present in an amount effective to inhibit platelet aggregation.

67. A compound of the formula: ##STR63## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is Har, G or Sar is Sar, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR64## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

68. A compound according to claim 67 having the formula: ##STR65##

69. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 68.

70. A compound comprising a platelet aggregation inhibitor of the formula: ##STR66## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is Har, G or Sar is Sar, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR67## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

71. A compound according to claim 70, the platelet aggregation inhibitor having the formula: ##STR68##

72. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 71.

73. A compound consisting essentially of a platelet aggregation inhibitor that inhibits (a) binding of Fg or vWF to GP IIb-IIIa more than (b) binding of vitronectin to vitronectin receptor or fibronectin to fibronectin receptor, which platelet aggregation inhibitor has the formula: ##STR69## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is Har, G or Sar is Sar, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR70## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

74. A compound according to claim 73, having the formula: ##STR71##

75. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 74.

76. A pharmaceutical composition which comprises a compound according to any of claim 67-75 in admixture with a pharmaceutically acceptable excipient.

77. The compound of claim 76, wherein said compound is present in an amount effective to inhibit platelet aggregation.

78. A compound of the formula: ##STR72## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is phenylimidyl-Lys, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR73## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

79. A compound according to claim 78 having the formula: ##STR74##

80. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 79.

81. A compound comprising a platelet aggregation inhibitor of the formula: ##STR75## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is phenylimidyl-Lys, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR76## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

82. A compound according to claim 81, the platelet aggregation inhibitor having the formula: ##STR77##

83. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 82.

84. A compound consisting essentially of a platelet aggregation inhibitor that inhibits (a) binding of Fg or vWF to GP IIb-IIIa more than (b) binding of vitronectin to vitronectin receptor or fibronectin to fibronectin receptor, which platelet aggregation inhibitor has the formula: ##STR78## wherein Y.sub.1 -X.sub.1 is Mpr, n1 is 0, K* is phenylimidyl-Lys, G or Sar is G, AA.sub.2 is W, n2 is 1, AA.sub.3 is a proline residue, n3 is 1, n4 is 0, X.sub.2 is C, Y.sub.2 is NH.sub.2, and ##STR79## represents a disulfide bond, or a physiologically acceptable basic or acid addition salt thereof.

85. A compound according to claim 84, having the formula: ##STR80##

86. A compound comprising a physiologically acceptable acid addition salt of the compound of claim 85.

87. A pharmaceutical composition which comprises a compound according to any of claim 78-86 in admixture with a pharmaceutically acceptable excipient.

88. The compound of claim 87, wherein said compound is present in an amount effective to inhibit platelet aggregation.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc